SightGlass Vision announced today that it received CE Mark approval in Europe for its eyeglasses for slowing myopia progression in children.
Palo Alto, Calif.-based SightGlass Vision touts its novel diffusion optics technology (DOT) spectacle lens products as the first of its kind to show success in a multi-center, randomized, controlled clinical trial to include options for myopia (nearsightedness) management.
In April, the company reported 12-month data from its Cypress clinical study that revealed a 74% reduction in myopia progression in both arms, plus a 50% reduction in axial length progression at 12 months in both arms as well, according to a news release from April 27.
“Our novel spectacle lenses designed to slow myopia progression in children have been hailed as a revolutionary innovation in the field of myopia management,” SightGlass Vision founder & CEO Thomas Chalberg said in a release today. “The CE Mark allowing Europea…